Nitrendipine – a modern calcium channel blocker
Authors:
Špinar J. 1; Špinarová L. 2; Vítovec J. 2
Authors‘ workplace:
Ústav fyziologie, LF MU Brno
1; Interní kardioangiologická klinika LF MU a FN u sv. Anny v Brně
2
Published in:
Kardiol Rev Int Med 2019, 21(4): 214-219
Overview
Calcium channel bockers belong among the five basic antihypertensive drug classes. They are divided into dihydropyridines, phenylalkylamines and benzothiazepines. They are used in monotherapy or in combination therapy, mainly with renin angiotensin aldosterone blockers, but also with diuretics or beta blockers. The most frequently used are dihydropyridines of the second generation; a representative of these is, for example nitrendipine. Nitrendipine was tested in a large clinical trial, SYST EUR in patients over 60 years of age and with isolated systolic hypertension; in comparison with hydrochlorothiazide, nitrendpine was more effective in lowering blood pressure but also for cardiovascular events, especially cerebrovascular events and cardiac events, including angina pectoris. The recommended dose of nitrendipine is 10–20 mg once daily.
Keywords:
hypertension – dihydropyridines – nitrendipine
Sources
1. Whelton PK, Carey RM, Aronow WS et al. 2017 ACC/ AHA/ AAPA/ ABC/ ACPM/AGS/APhA/ ASH/ ASPC/ NMA/ PCNA guideline for the prevention,detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/ American Heart Association Task Force on Clinical Practice Guidelines Hypertension. Hypertension 2018; 71(6): e13–e115. doi: 10.1161/ HYP.0000000000000065.
2. Widimský J jr, Filipovský J, Ceral J et al. Diagnostické a léčebné postupy u arteriální hypertenze – verze 2017. Doporučení České společnosti pro hypertenzi. Vnitř Lék 2018; 64(7–8): 771–796.
3. Williams B, Mancia G, Spiering W et al. 2018 ESC/ ESH Guidelines for themanagement of arterial hypertension: The Task Force for the management ofarterial hypertension of the European Society of Cardiology and the European Society Of Hypertension. J Hypertens 2018; 36(10): 1953–2041. doi: 10.1097/ HJH.000000000000194.
4. Staessen JA, Fagard R, Thijs L et al. The Systolic hypertension in Europe trial investigators. Randomised double blid comparison of placebo and active treatment in older patients with isolated systolic hypertension. Lancet 1997; 350(9080): 757–764. doi: 10.1016/ s0140-6736(97)05381-6.
5. Staessen JA, Thijs L, Fagard R et al. Predicting cardiovascular risk using conventional vs ambulatory blood presure in older patients with systolic hypertension. The Systolic hypertension in Europe trial investigators. JAMA 1999; 282(6): 539–546.
Labels
Paediatric cardiology Internal medicine Cardiac surgery CardiologyArticle was published in
Cardiology Review
2019 Issue 4
Most read in this issue
- Indapamide is not only a diuretic
- Propafenone
- News in the treatment of dyslipidaemia
- Management of asymptomatic arrhythmias – a shortened and commented consensus document of the European Heart Rhythm Association (EHRA)